Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured other health measures

A 12-week NMN trial in 108 older adults: all groups improved, afternoon NMN most

Kim and colleagues · Nutrients · 2022

Original title: Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Mixed

The 5-times sit-to-stand time improved in all groups, placebo included. Afternoon NMN had the largest effect on sit-to-stand (d = 0.72) and drowsiness (d = 0.64).

The study at a glance

Type of study
Randomized trial
Who or what was studied
108 people · Older Japanese adults
What was tested
NMN 250 mg once a day in the morning or afternoon for 12 weeks, vs placebo
What it measured
Other health or performance measures
Daily amount
250 mg a day
How long
12 weeks
Who has a stake
No stake declared
No conflicts of interest declared.
Journal
Nutrients, 2022
Source
PubMed record 35215405. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •Medium size: 108 people.
  • •Lasted 12 weeks.
  • •Measured other health measures, not aging and age-related decline itself.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 8 papers on the same step: 3 benefit, 1 mixed, 4 no difference. This one found mixed.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.